9C7F | pdb_00009c7f

Human monoclonal antibody MAD24-01 bound to the N-terminus of cleaved circumsporozoite protein

• PDB DOI: https://doi.org/10.2210/pdb9C7F/pdb

• Classification: IMMUNE SYSTEM
• Organism(s): Homo sapiens, Plasmodium falciparum 3D7
• Expression System: Cricetulus griseus
• Mutation(s): No 


• Deposited: 2024-06-10 Released: 2024-12-25 
• Deposition Author(s): Moskovitz, R., Wilson, I.A.
• Funding Organization(s): Bill & Melinda Gates Foundation

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 1.82 Å
• R-Value Free: 
  0.238 (Depositor), 0.240 (DCC) 
• R-Value Work: 
  0.211 (Depositor), 0.214 (DCC) 
• R-Value Observed: 
  0.212 (Depositor) 

Starting Model: in silico

Literature

Protective antibodies target cryptic epitope unmasked by cleavage of malaria sporozoite protein.

Dacon, C., Moskovitz, R., Swearingen, K., Da Silva Pereira, L., Flores-Garcia, Y., Aleshnick, M., Kanatani, S., Flynn, B., Molina-Cruz, A., Wollenberg, K., Traver, M., Kirtley, P., Purser, L., Dillon, M., Bonilla, B., Franco, A., Petros, S., Kritzberg, J., Tucker, C., Paez, G.G., Gupta, P., Shears, M.J., Pazzi, J., Edgar, J.M., Teng, A.A., Belmonte, A., Oda, K., Doumbo, S., Krymskaya, L., Skinner, J., Li, S., Ghosal, S., Kayentao, K., Ongoiba, A., Vaughan, A., Campo, J.J., Traore, B., Barillas-Mury, C., Wijayalath, W., Idris, A., Crompton, P.D., Sinnis, P., Wilder, B.K., Zavala, F., Seder, R.A., Wilson, I.A., Tan, J.

(2025) Science 387: eadr0510-eadr0510

• PubMed: 39745947 
• DOI: https://doi.org/10.1126/science.adr0510
• Primary Citation Related Structures: 
  9C79, 9C7D, 9C7F


• PubMed Abstract: 
  

  The most advanced monoclonal antibodies (mAbs) and vaccines against malaria target the central repeat region or closely related sequences within the Plasmodium falciparum circumsporozoite protein (PfCSP). Here, using an antigen-agnostic strategy to investigate human antibody responses to whole sporozoites, we identified a class of mAbs that target a cryptic PfCSP epitope that is only exposed after cleavage and subsequent pyroglutamylation (pGlu) of the newly formed N terminus. This pGlu-CSP epitope is not targeted by current anti-PfCSP mAbs and is not included in the licensed malaria vaccines. MAD21-101, the most potent mAb in this class, confers sterile protection against Pf infection in a human liver-chimeric mouse model. These findings reveal a site of vulnerability on the sporozoite surface that can be targeted by next-generation antimalarial interventions.

---

Organizational Affiliation: 
• Antibody Biology Unit, Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA.
Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA.
Institute for Systems Biology, Seattle, WA, USA.
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Department of Molecular Microbiology and Immunology and Johns Hopkins Malaria Institute, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Vaccine and Gene Therapy Institute, Oregon Health & Science University, Portland, OR, USA.
Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA.
Bioinformatics & Computational Biosciences Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA.
Department of Biology, The Catholic University of America, Washington, DC, USA.
Seattle Children's Research Institute, Seattle, WA, USA.
Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.
Antigen Discovery, Incorporated, Irvine, CA, USA.
General Dynamics Information Technology, Inc., Falls Church, VA, USA.
Agile Vaccines and Therapeutics Department, Naval Medical Research Command, Silver Spring, MD, USA.
Henry M Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, USA.
Mali International Center of Excellence in Research, University of Sciences, Technique and Technology of Bamako, Bamako, Mali.
Malaria Infection Biology and Immunity Section, Laboratory of Immunogenetics, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA.
The Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA.
The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA, USA.

Biological Assembly 1  

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Hetero 3-mer - A1B1C1 Pseudo Symmetry: Asymmetric - C1 
Pseudo Stoichiometry: Hetero 3-mer - A2B1 

Biological assembly 1 assigned by authors.

Biological Assembly 2  

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Hetero 3-mer - A1B1C1 Pseudo Symmetry: Asymmetric - C1 
Pseudo Stoichiometry: Hetero 3-mer - A2B1 

Biological assembly 2 assigned by authors.

Biological Assembly 3  

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Hetero 3-mer - A1B1C1 Pseudo Symmetry: Asymmetric - C1 
Pseudo Stoichiometry: Hetero 3-mer - A2B1 

Biological assembly 3 assigned by authors.

Biological Assembly 4  

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Hetero 3-mer - A1B1C1 Pseudo Symmetry: Asymmetric - C1 
Pseudo Stoichiometry: Hetero 3-mer - A2B1 

Biological assembly 4 assigned by authors.

Macromolecule Content 

• Total Structure Weight: 198.69 kDa 
• Atom Count: 15,148 
• Modeled Residue Count: 1,770 
• Deposited Residue Count: 1,820 
• Unique protein chains: 3

Macromolecules

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details	Image
Monoclonal antibody MAD24-01 Fab Heavy Chain	A [auth H], C [auth A], E [auth C], G [auth E]	225	Homo sapiens	Mutation(s): 0

Entity ID: 2
Molecule	Chains	Sequence Length	Organism	Details	Image
Monoclonal antibody MAD24-01 Fab Light Chain	B [auth L], D [auth B], F [auth D], H [auth F]	212	Homo sapiens	Mutation(s): 0

Entity ID: 3
Molecule	Chains	Sequence Length	Organism	Details	Image
Circumsporozoite protein	I [auth Q], J [auth G], K [auth I], L [auth J]	18	Plasmodium falciparum 3D7	Mutation(s): 0
UniProt
Find proteins for Q7K740 (Plasmodium falciparum (isolate 3D7)) Explore Q7K740  Go to UniProtKB:  Q7K740

Oligosaccharides

Help  

Entity ID: 4
Molecule	Chains	Length	2D Diagram	Glycosylation	D Interactions
2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose	M [auth K], N [auth M], O [auth N], P [auth O]	3		N/A
Glycosylation Resources
GlyTouCan: G21290RB GlyCosmos: G21290RB GlyGen: G21290RB

Small Molecules

Modified Residues  1 Unique
ID	Chains	Type	Formula	2D Diagram	Parent
PCA	A [auth H], C [auth A], E [auth C], G [auth E]	L-PEPTIDE LINKING	C5 H7 N O3		GLN

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 1.82 Å
• R-Value Free:  0.238 (Depositor), 0.240 (DCC) 
• R-Value Work:  0.211 (Depositor), 0.214 (DCC) 
• R-Value Observed: 0.212 (Depositor) 

Space Group: P 1 2₁ 1

Unit Cell:

Length ( Å )	Angle ( ˚ )
a = 74.541	α = 90
b = 88.32	β = 89.745
c = 168.952	γ = 90

Software Package:

Software Name	Purpose
PHENIX	refinement
DENZO	data reduction
SCALEPACK	data scaling
PHASER	phasing

Structure Validation

Entry History 

& Funding Information

Deposition Data

• Released Date: 2024-12-25 
Deposition Author(s): Moskovitz, R., Wilson, I.A.

---

Funding Organization	Location	Grant Number
Bill & Melinda Gates Foundation	United States	DAC-1601-INV-056202

Revision History  

• Version 1.0: 2024-12-25
  Type: Initial release
  
• Version 1.1: 2025-01-15
  Changes: Database references
• Version 1.2: 2025-01-22
  Changes: Database references